Tough Friday leads to a weak end to the week
The breakthrough that was thought to be possible on Thursday did not quite come to fruition on Friday. The DAX did not really know what to do with the economic guidelines from the USA, where inflation has also increased slightly again. While everything was still caught up in Trump euphoria on Thursday, investors are beginning to realize that this development could possibly endanger the Fed's soft landing. The DAX was therefore unable to make any further gains and closed the trading day down 0.2 percent at 19,219 points. The biggest losers in the index on Friday were Sartorius shares, which were the red lantern with a loss of 6 percent, and Qiagen and Merck shares, which lost 2.5 percent and 2.2 percent respectively in daily trading. The losses in the pharmaceutical sector are since Donald Trump appointed Robert Kennedy Jr., an outspoken vaccine skeptic, to his administration for the health sector.
European growth continues to dwindle
On the European stock market, it is becoming increasingly clear that the forecast weak growth is becoming more and more of a reality and the road back to better times could be rockier than expected. The growth reported from the UK is barely noticeable and is reported at 0.1 percent for the third quarter, while the EU is still sticking to the forecast growth of 0.8 percent for the coming year. From the Euro Stoxx, ASML had to give up some profits again with a loss of 5.5 percent, as did the shares of SAP AG, which also contributed to the weak trading day with a loss of 1.7 percent.
The information provided does not constitute investment research. The material has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and as such is to be considered to be a marketing communication.
All information has been prepared by ActivTrades (“AT”). The information does not contain a record of AT’s prices, or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information.
Any material provided does not have regard to the specific investment objective and financial situation of any person who may receive it. Past performance is not a reliable indicator of future performance. AT provides an execution-only service. Consequently, any person acting on the information provided does so at their own risk.